Sironax will present three datasets on SIR2501, an allosteric SARM1 inhibitor, reporting favorable safety, predictable pharmacokinetics and early biological activity in patients with amyotrophic lateral sclerosis and chemotherapy-induced peripheral neuropathy. SARM1 drives an active, enzymatically controlled axon destruction program rather than passive nerve decay, making it a tractable target. Preclinical neuroprotection was observed across ALS, glaucoma and ischemic stroke models, with Phase 1b/2 trials ongoing.
Key Points
- SARM1 inhibitor SIR2501 shows safety, early activity in ALS patients
- Early protective signals in chemotherapy-induced peripheral neuropathy reported
- Preclinical neuroprotection spans ALS, glaucoma and ischemic stroke models
Longevity Analysis
Axon degeneration is executed, not merely suffered: SARM1 consumes NAD+ locally once nerve fibers lose metabolic support, collapsing the energy supply that keeps projections alive. Holding that enzyme inactive removes a self-inflicted driver of neural loss rather than compensating for it downstream, which places this work closer to preserving regenerative capacity than to symptom management. The same pathway sits behind chemotherapy neuropathy, glaucomatous optic nerve loss and ischemic injury, so a single intervention point may protect nerve structure across conditions that otherwise appear unrelated.
Original published by LT Wire.